Subscribe to RSS
DOI: 10.1055/s-2008-1027994
© Georg Thieme Verlag KG Stuttgart · New York
Do We Need a Cancer Screening in Patients with Idiopathic Deep Vein Thrombosis?
Ist ein Tumor- Screening bei Patienten mit idiopathischer tiefer Venenthrombose nötig?Publication History
received: 6.5.2008
accepted: 23.10.2008
Publication Date:
28 January 2009 (online)

Zusammenfassung
Ziel: Eine Revision der Fachliteratur bezüglich des Bedarfs für ein Tumor-Screening zur Diagnose von nicht erkannten Tumorerkrankungen bei Patienten mit idiopathischer tiefer venöser Thromboembolie (VTE). Materialien und Methode: In der Studie wurden Daten von computergestützten Datenbanken (Medline, Ovid) bezogen und die Fachliteratur bezüglich der Studien über das Tumor-Screening bei Patienten mit idiopathischer VTE ausgewertet und unsere eigene Verfahrensweise hinzugefügt. Ergebnisse: Patienten mit einer VTE hatten eine höhere Malignitätsrate auch bei noch nicht diagnostizierten Tumoren. Bei den Nachkontrollen von Patienten mit VTE stieg das Vorkommen von Tumorerkrankungen und wurde gleichzeitig mit einer Verschlechterung der Prognose verbunden. Eine bedingte Diagnostik bei Patienten mit idiopathischer VTE ermöglicht die Diagnose von verborgenen Tumorleiden in ungefähr der Hälfte der untersuchten Fälle mit einer Sensitivität von 48 %. Ein ausführliches Tumor- Screening bei idiopathischer VTE dagegen führte zu weniger Zeitverzögerung und früherer Diagnose des Tumors mit einer Sensitivität von 93%. Eine erniedrigte tumorbedingte Sterblichkeit erwies sich bei diesen Patienten jedoch nicht als statistisch signifikant. Im Vergleich mit Patienten ohne einem Tumorleiden war bei Patienten mit VTE und nicht erkanntem Tumorleiden die Wahrscheinlichkeit einer tödlichen Lungenembolie war auf das Doppelte, die einer fatalen Blutung auf mehr als das Dreifache erhöht. Die Risikofaktoren für nicht erkannte Tumorleiden sind: hohes Alter, Anämie, idiopathische und beidseitige tiefe Venenthrombosen. Schlussfolgerungen: Es besteht kein Konsens bezüglich der Vorteile eines ausgedehnten Screenings bei Patienten mit einer idiopathischen VTE. Klare diagnostische Richtlinien bestehen noch nicht. Eine kosteneffektiver diagnostischer Algorhythmus für ein Tumor -Screening bei Patienten mit idiopathischer VTE ist erforderlich.
Abstract
Aim: To review the literature concerning the need for a cancer screening battery to diagnose a hidden cancer in patients presenting with idiopathic venous thromboembolism (VTE). Materials and Methods: Data from computerized database programs (Medline, Ovid) was retrieved. A review of the literature regarding studies on cancer screening in patients with idiopathic VTE was performed and our own policy included. Results: Patients with VTE have a higher rate of malignancy which may still be undiagnosed. During follow-up of patients with idiopathic VTE, the incidence of cancer increases and is more likely associated with a worse prognosis. Limited diagnostic work-up in patients with idiopathic VTE allows the diagnosis of a hidden malignancy in about half of the cases with a sensitivity of 48 %. Extensive screening of cancer with idiopathic VTE allows less of a delay and earlier stage at diagnosis with a 93 % sensitivity. However, reduced cancer-related mortality is not statistically significant. A two-fold fatal PE and more than 3-fold fatal bleeding are registered in VTE patients with hidden cancer compared to patients without cancer. The major risk factors for hidden cancer are old age, anemia, idiopathic and bilateral deep vein thrombosis. Conclusion: There is no consensus regarding the benefit of extensive screening in patients presenting with idiopathic VTE. Clear diagnostic work-up guidelines are not yet available. A cost-effective diagnostic algorithm for cancer screening in patients with idiopathic VTE is needed.
Key words
veins - diagnostic radiology - screening - tumor - ultrasound Doppler
References
- 1 Trousseau A. Phlegmatia alba dolens. Peter M Clinique Médicale de l’Hotel-Dieu de Paris Paris; J. B. Balliè re et fils 1877: 695-739
Reference Ris Wihthout Link
- 2
Caine G J, Stonelake P S, Lip G YH. et al .
The hypercoagulable state of malignancy: pathogenesis and current debate.
Neoplasia.
2002;
4
465-473
Reference Ris Wihthout Link
- 3
De Cicco M.
The prothrombotic state in cancer: pathogenesis mechanisms.
Critical Reviews in Oncology and Hematology.
2004;
50
187-196
Reference Ris Wihthout Link
- 4
Falanga A, Rickels F R.
Pathophysiology of the thrombophilic state in cancer patients.
Semin Thromb Hemost.
1999;
25
173-182
Reference Ris Wihthout Link
- 5
Haim N, Lanir N, Hoffman R. et al .
Acquired activated protein C resistance is common in cancer patients and is associated
with venous thromboembolism.
Am J Med.
2001;
110
91-96
Reference Ris Wihthout Link
- 6
Lee A YY, Levine M.
The thrombophilic state induced by therapeutic agents in the cancer patient.
Semin Thromb Hemost.
1999;
25
137-145
Reference Ris Wihthout Link
- 7
Nadir Y, Brenner B, Zetser A. et al .
Heparanase induces tissue factor expression in vascular endothelial and cancer cells.
J Thromb Haemost.
2006;
11
2443-2451
Reference Ris Wihthout Link
- 8
Illtyd J ames T, Matheson N.
Thrombo-phlebitis in cancer.
Practitioner.
1935;
134
683-684
Reference Ris Wihthout Link
- 9
Piccioli A, Prandoni P.
Occult cancer and idiopathic venous thromboembolism.
Hematologica reports.
2005;
1
2-4
Reference Ris Wihthout Link
- 10
Otten H M, Prins M H.
Venous thromboembolism and occult malignancy.
Thromb Res.
2001;
102
V187-V194
Reference Ris Wihthout Link
- 11
Monreal M.
Screening for occult cancer in patients with acute venous thromboembolism.
J Thromb Haemost.
2005;
3
2389-2390
Reference Ris Wihthout Link
- 12
Lee A YY, Levin M N.
Venous thromboembolism and cancer: risks and outcomes.
Circulation.
2003;
107
I-17–I-21
Reference Ris Wihthout Link
- 13
Prandoni P, Lensing A W, Buller H R. et al .
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.
N Engl J Med.
1992;
327
1128-1133
Reference Ris Wihthout Link
- 14
Sorensen H T, Mellemkjaer L, Olsen J H. et al .
Prognosis of cancer associated venous thromboembolism.
N Engl J Med.
2000;
343
1846-1850
Reference Ris Wihthout Link
- 15
Kolomansky A, Hoffman R, Sarig G. et al .
Prospective evaluation of patients hospitalized with venous thromboembolism: comparison
between cancer and non-cancer patients.
Isr Med Assoc J.
2006;
8
848-852
Reference Ris Wihthout Link
- 16
Aderka D, Brown A, Zelikovski A. et al .
Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory
sign of occult cancer.
Cancer.
1986;
57
1846-1849
Reference Ris Wihthout Link
- 17
Ahmed Z, Mohyuddin Z.
Deep vein thrombosis as a predictor of cancer.
Angiology.
1996;
47
261-265
Reference Ris Wihthout Link
- 18
Monreal M, Lafoz E, Casals A. et al .
Occult cancer in patients with deep venous thrombosis. A systematic approach.
Cancer.
1991;
67
541-545
Reference Ris Wihthout Link
- 19
Hettiarachchi R J, Lok J, Prins M H. et al .
Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators
and diagnosis.
Cancer.
1998;
83
180-185
Reference Ris Wihthout Link
- 20
Rajan R, Levine M, Gent M. et al .
The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis:
results from a historical cohort study.
Thromb Haemost.
1998;
79
19-22
Reference Ris Wihthout Link
- 21
Schulman S, Lindmarker P.
Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism.
N Engl J Med.
2000;
342
1953-1958
Reference Ris Wihthout Link
- 22
Oudega R, Moons K G, Nieuwenhuis H. et al .
Deep vein thrombosis in primary care: possible malignancy?.
Br J Gen Pract.
2006;
56
693-696
Reference Ris Wihthout Link
- 23
Monreal M, Lensing A W, Prins M H. et al .
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary
embolism.
J Thromb Haemost.
2004;
2
876-881
Reference Ris Wihthout Link
- 24
Piccioli A, Lensing A WA, Prins M H. et al .
SOMIT Investigators Group. Extensive screening for occult malignant disease in idiopathic
venous thromboembolism: a prospective randomized clinical trial.
J Thromb Haemost.
2004;
2
884-889
Reference Ris Wihthout Link
- 25
Monreal M, Suárez C, Fajardo J A. et al .
RIETE Investigators. Management of patients with acute venous thromboembolism: findings
from the RIETE registry.
Pathophysiol Haemost Thromb.
2003 / 2004;
33
330-334
Reference Ris Wihthout Link
- 26
Monreal M, Falga C, Vilasecca B. et al .
RIETE Investigators. Clinical outcomes in cancer patients with concurrent venous thromboembolism:
findings from the RIETE registry.
Hematologica reports.
2005;
1
64-65
Reference Ris Wihthout Link
- 27
Monreal M, Falga C, Valdes M. et al .
RIETE Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients
with venous thromboembolism: Findings from the RIETE registry.
J Thromb Haemost.
2006;
4
1950-1956
Reference Ris Wihthout Link
- 28
Trujillo-Santos J, Prandoni P, Rivron-Guillot K. et al .
RIETE Investigators. Clinical outcome in patients with venous thromboembolism and
hidden cancer: findings from the RIETE Registry.
J Thromb Haemost.
2008;
6
251-255
Reference Ris Wihthout Link
- 29
Piccioli A, Prandoni P.
Screening for occult cancer in patients with idiopathic venous thromboembolism:yes.
J Thromb Haemost.
2003;
1
2271-2272
Reference Ris Wihthout Link
- 30
Lee A YY.
Screening for occult cancer in patients with idiopathic venous thromboembolism: no.
J Thromb Haemost.
2003;
1
2273-2274
Reference Ris Wihthout Link
- 31
Monreal M, Fernandez-Llamazares J, Perandreu J. et al .
Occult cancer in patients with venous thromboembolism: which patients, which cancers.
Tromb Haemost.
1997;
78
1316-1318
Reference Ris Wihthout Link
Dr. Diana E Gaitini
Radiology, Rambam Medical Center
Hahalya Hasnia 8
31096 Haifa
Israel
Phone: ++ 9 72/4/8 54 36 75
Fax: ++ 9 72/4/8 54 33 03
Email: d_gaitini@rambam.health.gov.il